大规模临床确诊卵巢癌病例多基因panel检测的突变频率与参考对照比较
研究对7768例欧洲血统成人卵巢癌病例进行19个已知或疑似卵巢癌易感基因的多基因panel检测,并与ExAC对照比较突变频率。发现11个基因的致病变异与卵巢癌显著相关(p<0.001),其中8个基因风险增加≥5倍;ATM风险大于2倍,而RAD50和CHEK2可可靠排除关联。
要点
- 7768例欧洲血统卵巢癌病例中,11个基因致病变异与卵巢癌显著关联(p<0.001)。
- BRCA1、BRCA2、BRIP1、MSH2、MSH6、RAD51C、RAD51D等8个基因风险增加≥5倍。
- ATM风险大于2倍,RAD50和CHEK2的关联可可靠排除。
核心结论
- 多基因panel检测的某些基因致病变异与卵巢癌相关,部分基因无关联可减少携带者的担忧。
研究设计与样本
- 7768例欧洲血统成人卵巢癌病例,转诊至单一临床检测实验室,采用靶向捕获法检测19个基因的致病或可能致病变异,并与ExAC个体突变频率比较。
主要发现
- 11个基因的变异与卵巢癌显著关联(p<0.001),其中8个基因风险增加≥5倍(BRCA1、BRCA2、BRIP1、MSH2、MSH6、RAD51C、RAD51D)。
- ATM的卵巢癌相对风险大于2倍,RAD50和CHEK2的关联可可靠排除。
关键数值与推荐
- 显著关联阈值p<0.001;8个基因风险增加≥5倍;ATM风险大于2倍。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Given the lack of adequate screening modalities, knowledge of ovarian cancer risks for carriers of pathogenic alterations in predisposition genes is important for decisions about risk-reduction by salpingo-oophorectomy. We sought to determine which genes assayed on multi-gene panels are associated with ovarian cancer, the magnitude of the associations, and for which clinically meaningful associations could be ruled out. METHODS: 7768 adult ovarian cancer cases of European ancestry referred to a single clinical testing laboratory underwent multi-gene panel testing for detection of pathogenic alterations in known or suspected ovarian cancer susceptibility genes. A targeted capture approach was employed to assay each of 19 genes for the presence of pathogenic or likely pathogenic alterations. Mutation frequencies in ovarian cancer cases were compared to mutation frequencies in individuals from the Exome Aggregation Consortium (ExAC). Analyses stratified by family and personal history of other cancers and age at diagnosis were also performed. RESULTS: Significant associations (p<0.001) were identified between alterations in 11 genes and ovarian cancer, with eight of these displaying ≥5-fold increased risk (BRCA1, BRCA2, BRIP1, MSH2, MSH6, RAD51C, RAD51D). Relative risks of ovarian cancer greater than two-fold were also observed for ATM, but could reliably be ruled out for RAD50 and CHEK2. CONCLUSIONS: These results will inform clinical management of women found to carry pathogenic alterations in genes tested on multi-gene panels. The knowledge that some genes are not associated with OC can reduce concerns of women found to carry pathogenic alterations in those genes.
引用
- Lilyquist J, LaDuca H, Polley E, et al. Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls. Gynecol Oncol. 2017. PMID: 28888541. doi:10.1016/j.ygyno.2017.08.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。